Plasmid News and Research

RSS

Nanoparticle-enabled peptide delivery triggers tumor regression

Cells possess a variety of ways of dealing with mutations that can cause them to grow uncontrollably and eventually form a tumor. The tumor suppressor gene p53 plays a critical role in these cancer prevention processes, largely by triggering a form a cell death known as apoptosis.

14 Jun 2007

Sangamo BioSciences starts phase 2 trial of therapy diabetic neuropathy

Sangamo BioSciences has announced that the company has initiated a repeat-dosing, multi-center Phase 2 clinical trial of SB-509 in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN).

27 Apr 2007

Nanoparticle delivery system delivers cancer-suppressing gene in M. D. Anderson trial

A cancer-suppressing gene has been successfully delivered into the tumors of stage 4 lung cancer patients via an intravenously administered lipid nanoparticle in a phase I clinical trial at The University of Texas M. D. Anderson Cancer Center.

18 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Gelatin-based nanoparticles deliver therapeutic genes to human breast cancer

Northeastern University professor Mansoor Amiji and graduate student Sushma Kommareddy have published a new paper that examines the potential of engineered gelatin-based nanoparticles to deliver therapeutic genes to human breast cancer tumors implanted in mice.

14 Apr 2007

New patented technology for next generation of DNA and RNA microarrays

A novel invention developed by a scientist from New York Institute of Technology (NYIT) could revolutionize biological and clinical research and may lead to treatments for cancer, AIDS, Alzheimer's, diabetes, and genetic and infectious diseases.

13 Feb 2007

NanoMed Pharmaceuticals issued new U.S. nanoparticle patent

NanoMed Pharmaceuticals has announced that founders Russell J. Mumper, Ph.D. and Michael Jay, Ph.D. have been issued U.S. Patent 7,153,525 entitled "Microemulsions As Precursors To Solid Nanoparticles."

3 Jan 2007

Study shows how the plague bacteria Yersinia pestis causes disease

The bacteria responsible for the plague and some forms of food poisoning "paralyze" the immune system of their hosts in an unexpected way, according to a new study in the September 8, 2006 issue of the journal Cell.

7 Sep 2006

Swedish HIV vaccine study shows prmoise

A Swedish HIV vaccine study conducted by researchers at Karolinska Institutet (KI), Karolinska University Hospital and the Swedish Institute for Infectious Disease Control (SMI) has produced surprisingly good results.

30 Aug 2006

West Nile virus DNA vaccine shows promise in phase 1 trial

Vical Incorporated has announced that in a Phase 1 clinical trial, a West Nile virus (WNV) vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated

5 Jun 2006

A putative RNA-interference-based immune system in prokaryotes

Researchers have used computational methods to predict what could be a prokaryotic RNA-silencing mechanism similar to the eukaryotic RNA- interference system.

20 Mar 2006

Innovative treatment for critical limb ischemia

A new randomized study presented at the American College of Cardiology's 55th Annual Scientific Session investigates an innovative treatment for critical limb ischemia, or lack of arterial blood supply and oxygen to the legs, using a therapeutic approach to generate new blood vessels.

14 Mar 2006

Wobble pairs make RNA more reactive

The wealth of information contained in a strand of genetic material boils down to sequences of matched pairs of nucleotides that cellular machinery decodes to construct proteins.

13 Mar 2006

World's deadliest malaria parasite cloaking gene revealed

The world's deadliest malaria parasite, Plasmodium falciparum, sneaks past the human immune system with the help of a wardrobe of invisibility cloaks. If a person's immune cells learn to recognize one of the parasite's many camouflage proteins, the surviving invaders can swap disguises and slip away again to cause more damage. Malaria kills an estimated 2.7 million people annually worldwide, 75 percent of them children in Africa.

29 Dec 2005

Artificial mammalian origin of replication

A collaboration of researchers from Harvard Medical School and the University of Virginia, led by Dr. Anindya Dutta, has created an artificial mammalian origin of replication that will facilitate the future study of mammalian DNA replication.

2 Dec 2005

New way to generate genetically altered influenza virus

In the event of an influenza pandemic, the world's vaccine manufacturers will be in a race against time to forestall calamity.

1 Nov 2005

Gene therapy may prevent the damaging effects of radiation

Gene therapy could be used as an agent to protect normal tissues, including the esophagus and lung, from damage during a second administration of radiation therapy for non-small cell lung cancer, according to an animal study presented by University of Pittsburgh researchers at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Denver.

16 Oct 2005

Deadly 1918 Spanish flue virus has been reconstructed and characterized

This research, reported in this week's issue of Science, is part of a larger research initiative being led by Adolfo Garcia-Sastre, PhD, Professor of Microbiology and Peter Palese, PhD, Professor and Chairman of Microbiology at Mount Sinai School of Medicine.

5 Oct 2005

Vical receives $12 Million HIV vaccine order

Vical Incorporated announced today the receipt of approximately $12.1 million in production orders for multiple clinical lots of DNA vaccines against HIV for the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, under a subcontract managed by SAIC-Frederick, Inc.

16 Jun 2005

FDA grants Vical orphan-drug designation

Vical Incorporated today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has designated the company's bivalent (two-plasmid) formulation of the company's vaccine against cytomegalovirus (CMV) as an orphan drug for the prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant (HCT) and solid organ transplant (SOT) populations.

14 Jun 2005